Pillars of long-term antiretroviral therapy success
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Meeting the challenge of antiretroviral therapy (ART) whose efficacy can last a lifetime requires continuous updating of the virological, pharmacological, and quality of life outcomes to be pursued and a continuous review of literature data on the efficacy and tolerability of new drugs and therapeutic strategies.
METHODS: With the aim of identifying open questions and answers about the current controversies in modern ART, we adapted the Design Thinking methodology to the needs of the design phase of a scientific article, involving a team of experts in HIV care.
RESULTS: Five main pillars of treatment success were discussed: sustained virologic suppression over time; immunological recovery; pharmacological attributes; long-term tolerability and safety of ART; and people's satisfaction and quality of life. The definition of the outcomes to be achieved in each thematic area and the tools to achieve them were reviewed and discussed.
CONCLUSIONS: Long-term treatment success should be intended as a combination of HIV-RNA suppression, immune recovery, and high quality of life. To achieve this, the regimen should be well-tolerated, with high potency, genetic barrier, and forgiveness, and should be tailored by a person-centered perspective, based on individual needs, preferences, and therapeutic history.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:196 |
|---|---|
| Enthalten in: |
Pharmacological research - 196(2023) vom: 28. Okt., Seite 106898 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antiretroviral therapy |
|---|
| Anmerkungen: |
Date Revised 13.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.phrs.2023.106898 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361459661 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361459661 | ||
| 003 | DE-627 | ||
| 005 | 20231226085201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2023.106898 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361459661 | ||
| 035 | |a (NLM)37648103 | ||
| 035 | |a (PII)S1043-6618(23)00254-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Taramasso, Lucia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pillars of long-term antiretroviral therapy success |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Meeting the challenge of antiretroviral therapy (ART) whose efficacy can last a lifetime requires continuous updating of the virological, pharmacological, and quality of life outcomes to be pursued and a continuous review of literature data on the efficacy and tolerability of new drugs and therapeutic strategies | ||
| 520 | |a METHODS: With the aim of identifying open questions and answers about the current controversies in modern ART, we adapted the Design Thinking methodology to the needs of the design phase of a scientific article, involving a team of experts in HIV care | ||
| 520 | |a RESULTS: Five main pillars of treatment success were discussed: sustained virologic suppression over time; immunological recovery; pharmacological attributes; long-term tolerability and safety of ART; and people's satisfaction and quality of life. The definition of the outcomes to be achieved in each thematic area and the tools to achieve them were reviewed and discussed | ||
| 520 | |a CONCLUSIONS: Long-term treatment success should be intended as a combination of HIV-RNA suppression, immune recovery, and high quality of life. To achieve this, the regimen should be well-tolerated, with high potency, genetic barrier, and forgiveness, and should be tailored by a person-centered perspective, based on individual needs, preferences, and therapeutic history | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antiretroviral therapy | |
| 650 | 4 | |a Immunological recovery | |
| 650 | 4 | |a Pharmacological attributes | |
| 650 | 4 | |a Quality of life | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a Virologic suppression | |
| 700 | 1 | |a Andreoni, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Antinori, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Bandera, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Bonfanti, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Bonora, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Borderi, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Castagna, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Cattelan, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Celesia, Benedetto Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Cicalini, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Cingolani, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Cossarizza, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a D'Arminio Monforte, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a D'Ettorre, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Di Biagio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Di Giambenedetto, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Di Perri, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Esposito, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Focà, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Gervasoni, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Gori, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Gianotti, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Guaraldi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Gulminetti, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Lo Caputo, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Madeddu, Giordano |e verfasserin |4 aut | |
| 700 | 1 | |a Maggi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Marandola, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetti, Giulia Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Mastroianni, Claudio Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Mussini, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Perno, Carlo Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzardini, Giuliano |e verfasserin |4 aut | |
| 700 | 1 | |a Rusconi, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Sarmati, Loredana |e verfasserin |4 aut | |
| 700 | 1 | |a Zazzi, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Maggiolo, Franco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological research |d 1992 |g 196(2023) vom: 28. Okt., Seite 106898 |w (DE-627)NLM012597384 |x 1096-1186 |7 nnns |
| 773 | 1 | 8 | |g volume:196 |g year:2023 |g day:28 |g month:10 |g pages:106898 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phrs.2023.106898 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 196 |j 2023 |b 28 |c 10 |h 106898 | ||